secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2022-03-28T23:59:59+00:00
Accession:  0001193125-22-086679
Event type: leadership
Sentiment:  negative
Materiality: 0.85
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics CEO Mallon steps down; Q1 revenue to miss guidance; 2022 outlook withdrawn
--------------------------------------------------------------------------------

- CEO Mark Mallon steps down effective immediately; Board appoints Lynn Tetrault as Executive Chair, forms Office of the CEO with three executives.
- Q1 2022 revenue expected below prior guidance of $118-120M; EBITDA below guidance of ($15)-($12)M, primarily due to higher Clinical Services COGS.
- Company withdraws full-year 2022 financial guidance issued Feb 23, 2022; will report Q1 results on Apr 27.
- Separation agreement: Mallon receives $775K base salary + $775K target bonus, plus accelerated vesting of certain equity awards.
- Board retains Russell Reynolds to conduct CEO search.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000119312522086679/0001193125-22-086679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000119312522086679/d312815d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-086679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer